Abbott Laboratories Beats Q2 Estimates and Raises Full-Year 2026 Guidance

Key Facts

1Abbott Laboratories reported Q2 adjusted EPS of $1.31 and revenue of $12.59 billion, surpassing analyst expectations.

2The company raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60.

3TD Cowen reiterated a Buy rating on the stock with a price target of $135.00.

Abbott Laboratories reported Q2 2026 adjusted earnings per share of $1.31 and revenue of $12.59 billion, surpassing analyst expectations. AD HOC NEWS reported that the company subsequently raised its full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60.

ABT closed at $100.95 on September 29, 2026, while TD Cowen reiterated a Buy rating on the stock with a price target of $135.00. The quarterly performance was driven by an 8.40% growth in the Medical Devices segment, which offset a 3.60% decline in the Nutrition division.